Holen Sie sich die Stockscreener-App
24.88
1.15%
-0.31
Schlusskurs vom Vortag:
$25.19
Offen:
$25.46
24-Stunden-Volumen:
485.82K
Relative Volume:
0.19
Marktkapitalisierung:
$3.06B
Einnahmen:
$1.12B
Nettoeinkommen (Verlust:
$5.00M
KGV:
2,488.00
EPS:
0.01
Netto-Cashflow:
$-383.00M
1W Leistung:
+3.11%
1M Leistung:
+9.35%
6M Leistung:
+174.83%
1J Leistung:
+205.90%
1-Tages-Spanne:
$24.53
$25.49
1-Wochen-Bereich:
$22.95
$25.49
52-Wochen-Spanne:
$7.62
$25.49
Indivior Plc Stock (INDV) Company Profile
Firmenname
Indivior Plc
Sektor
Telefon
804-379-1090
Adresse
234 BATH ROAD, SLOUGH, BERKSHIRE
Vergleichen Sie INDV mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INDV
Indivior Plc
|
24.88 | 3.06B | 1.12B | 5.00M | -383.00M | 0.01 |
|
ZTS
Zoetis Inc
|
143.33 | 63.58B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.93 | 43.58B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.235 | 40.83B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
19.86 | 23.07B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
431.45 | 19.61B | 3.08B | 1.24B | 1.07B | 25.61 |
Indivior Plc Stock (INDV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-07-22 | Fortgesetzt | Jefferies | Buy |
| 2025-01-28 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-07-23 | Eingeleitet | Piper Sandler | Overweight |
| 2024-04-03 | Eingeleitet | Craig Hallum | Buy |
| 2023-07-13 | Eingeleitet | Northland Capital | Outperform |
Alle ansehen
Indivior Plc Aktie (INDV) Neueste Nachrichten
Indivior Q2 2025 presentation: SUBLOCADE growth drives raised guidance By Investing.com - Investing.com Nigeria
Indivior stock hits 52-week high at 25.1 USD By Investing.com - Investing.com Nigeria
Indivior stock hits 52-week high at 25.1 USD - Investing.com
Using AI based signals to follow Indivior PLCPortfolio Risk Report & Real-Time Stock Entry Alerts - newser.com
How Indivior PLC stock trades during market volatilityWeekly Trade Recap & High Accuracy Investment Entry Signals - newser.com
Clinical Evidence Supports Rapid SUBLOCADE Induction As A Strategy To Improve Retention In Opioid Use Disorder Treatment - TradingView
Clinical Evidence Supports Rapid SUBLOCADE® Induction as a Strategy to Improve Retention in Opioid Use Disorder Treatment (2025-10-15) - Seeking Alpha
Can Indivior PLC stock reach $100 price targetEarnings Growth Report & Free Community Consensus Stock Picks - newser.com
News impact scoring models applied to Indivior PLCWeekly Loss Report & Daily Chart Pattern Signal Reports - newser.com
Using Python tools to backtest Indivior PLC strategiesJuly 2025 Patterns & Intraday High Probability Setup Alerts - newser.com
Is Indivior PLC stock reversal real or fake2025 Market WrapUp & Safe Capital Growth Tips - newser.com
Earnings call transcript: Indivior’s Q2 2025 revenue rises, guidance boosted - Investing.com
Earnings call transcript: Indivior’s Q2 2025 revenue rises, guidance boosted By Investing.com - Investing.com Canada
Will Indivior PLC stock deliver long term returnsJuly 2025 Outlook & Short-Term High Return Strategies - newser.com
Substance Abuse Treatment Market to Witness Remarkable Growth With Indivior PLC, Pfizer, Inc. - openPR.com
Chart based exit strategy for Indivior PLCEarnings Trend Report & Scalable Portfolio Growth Methods - newser.com
How Indivior PLC stock performs in rising dollar environment2025 EndofYear Setup & Weekly Market Pulse Alerts - newser.com
Indivior targets $1.5B peak revenue for Sublocade amid 2025 transition plans - MSN
Will Indivior PLC stock rally after Fed decisionsMarket Weekly Review & Weekly Momentum Picks - newser.com
Will Indivior PLC benefit from macro trendsJuly 2025 Analyst Calls & Low Risk Investment Opportunities - newser.com
Strategies to average down on Indivior PLCJuly 2025 Review & Target Return Focused Picks - newser.com
Indivior PLC stock outlook for YEARTrade Exit Summary & Entry Point Confirmation Alerts - newser.com
Will Indivior PLC outperform the marketJuly 2025 Action & Expert Curated Trade Setups - newser.com
What indicators show strength in Indivior PLCTrade Analysis Report & Daily Volume Surge Signals - newser.com
U.S. Suboxone Market Set to See Booming Growth 2025-2032 Driven by Key Players like Indivior, Teva, and Alcami - openPR.com
Substance Abuse Treatment Market Size, Growth Analysis 2031 - openPR.com
What the charts say about Indivior PLC today2025 Risk Factors & Growth-Oriented Investment Plans - newser.com
Indivior Launches Action Agenda for Business Enhancement - MSN
What analysts say about Indivior PLC stockHigh Dividend Yield Stocks & Big Profit Small Budget - earlytimes.in
Automated trading signals detected on Indivior PLC2025 Short Interest & Daily Volume Surge Trade Alerts - newser.com
Full technical analysis of Indivior PLC stockJuly 2025 Short Interest & Safe Capital Growth Trade Ideas - newser.com
Why Indivior PLC stock remains resilient2025 Retail Activity & Safe Investment Capital Preservation Plans - newser.com
Should you wait for a breakout in Indivior PLC2025 Trading Recap & Stock Portfolio Risk Control - newser.com
Can momentum traders help lift Indivior PLCMarket Risk Report & Fast Moving Stock Watchlists - newser.com
Indivior PLC (INDV) Raises 2025 Guidance After Q2 Revenue Hits $302M - MSN
US AG stops misleading marketing of unauthorized opioid overdose drug by Indivior - The Pharma Letter
Indivior plans U.S. domicile shift from U.K. to enhance Nasdaq presence - Investing.com Nigeria
UK's Indivior to re-domicile to US after listing move - Global Banking | Finance | Review
Opvee, High-Profile Overdose Antidote No One Used, Discontinues Marketing - Filter
UK’s Indivior to re-domicile to US after listing move - 104.1 WIKY
Indivior proposes new corporate structure to achieve U.S. domiciliation - MarketScreener
Finanzdaten der Indivior Plc-Aktie (INDV)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.53%
0.97%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):